AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
TG Therapeutics Q2 rev up 8.5% YoY to $141.1mln, raises FY25 BRIUMVI target to $570-$575mln.
ByAinvest
Monday, Aug 4, 2025 7:03 am ET1min read
• TG Therapeutics Q2 2025 revenue: $141.1 million • BRIUMVI US net revenue: $138.8 million • Raises FY 2025 BRIUMVI US net revenue target: $570-$575 million • Strong uptake and physician confidence in BRIUMVI • Update on 2025 revenue guidance provided • Conference call to be held on August 4, 2025, at 8:30 AM ET
TG Therapeutics (NASDAQ: TGTX) has released its second-quarter (Q2) 2025 financial results, showcasing robust performance and raising its full-year 2025 revenue guidance. The biopharmaceutical company reported total revenue of $141.1 million, with BRIUMVI U.S. net revenue reaching $138.8 million, representing a 91% year-over-year growth and 16% growth over Q1 2025 [2].The company's flagship product, BRIUMVI, has seen strong uptake and physician confidence, contributing significantly to the revenue growth. TG Therapeutics has updated its full-year 2025 BRIUMVI U.S. net revenue target to approximately $570-$575 million, reflecting the positive market reception and clinical trial advancements [2].
The Q2 2025 financial results also include net income of $28.2 million and a strong cash position of $278.9 million. The company's pipeline is advancing with new clinical trials, including a Phase 3 program for consolidated BRIUMVI dosing and development of a subcutaneous formulation [2].
TG Therapeutics will host a conference call on August 4, 2025, at 8:30 AM ET, to discuss the financial results and provide an update on 2025 revenue guidance. Investors and financial professionals are encouraged to participate to gain further insights into the company's performance and future prospects.
References:
[1] https://www.marketbeat.com/instant-alerts/tg-therapeutics-tgtx-to-release-quarterly-earnings-on-tuesday-2025-07-29/
[2] https://www.stocktitan.net/news/TGTX/tg-therapeutics-reports-second-quarter-2025-financial-results-and-gk27yackstrn.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet